Status:
COMPLETED
Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resect...
Detailed Description
This is a non-interventional, multi-country, multicentre, retrospective study designed to determine the treatment patterns and associated survival rate in patients with primary stage IA to IIIB resect...
Eligibility Criteria
Inclusion
- Adult female and male patients aged ≥18 years or 'adults' according to age of majority as defined by the local regulations on index date
- Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written or electronic informed consent according to the local regulations, where applicable
- Patients diagnosed with primary stage IA to IIIB NSCLC as per seventh edition AJCC whose tumour was deemed resectable between 01 January 2013 and 31 December 2017 and followed up until at least 31 December 2020, as per the medical records with availability of at least 12 months of follow-up data from the index date (date of diagnosis of early-stage \[IA to stage IIIB\] resectable NSCLC), unless patient died within 12 months of diagnosis.
Exclusion
- Patients with a concomitant cancer at the time of diagnosis of NSCLC, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms; a cancer will be considered concomitant if it occurs within 5 years of NSCLC diagnosis
- Patients diagnosed with stage IV NSCLC
- Histology of the tumour is small cell lung cancer, neuroendocrine in origin, or a mixed histologic type with small cell and non-small cell lung cancers.
Key Trial Info
Start Date :
November 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
748 Patients enrolled
Trial Details
Trial ID
NCT04808050
Start Date
November 3 2021
End Date
October 31 2022
Last Update
February 21 2024
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Sydney, New South Wales, Australia
2
Research Site
Brisbane, Queensland, Australia
3
Research Site
Perth, Western Australia, Australia
4
Research Site
Alexandria, Egypt